Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 8Completed 5Unknown 4Not yet recruiting 3

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Solid Tumor 87Advanced Solid Tumor 80Advanced Solid Tumors 70Mesothelioma, Malignant 41Solid Tumor, Adult 29Mesothelioma 28Solid Tumors 24Unspecified Adult Solid Tumor, Protocol Specific 21Retinoblastoma 19Carcinoma, Non-Small-Cell Lung 11Stomach Neoplasms 9Ovarian Neoplasms 8Advanced Malignant Solid Tumors 7Advanced Malignant Solid Tumor 7Pancreatic Neoplasms 6Melanoma 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Lung Neoplasms 5Locally Advanced or Metastatic Solid Tumors 5Esophageal Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Pleural Effusion, Malignant 4Malignant Solid Tumors 4Lymphoma 4Carcinoma, Hepatocellular 4Unspecified Childhood Solid Tumor, Protocol Specific 3

Interventions

tislelizumab 1Sirolimus 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Malignant Solid Tumors × Other solid neoplasm × Clear all
NCT06082557 2023-10-13

A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Unknown
62 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT05508620 2022-08-23

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1 Unknown
270 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT05441046 2022-07-06

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1 Unknown
120 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT01694472 2015-12-22

Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

Tianjin Medical University Cancer Institute and Hospital

Phase 1 Unknown
15 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡